A patient with a bloodstream infection is administered an antibiotic that may not be effective against the causative pathogen. A rapid diagnostic test identifies the organism and detects a resistance marker hours before conventional testing would provide comparable information. This finding suggests that the current treatment may need to change, but whether it actually does depends on what happens next.
The result must reach someone who can interpret it, assess its implications for the patient’s treatment, and make an appropriate clinical decision. That person may need additional susceptibility information, guidance from an antimicrobial stewardship team, or access to an alternative drug. Each step introduces the possibility of delay, even after the diagnostic technology has performed exactly as intended.
The consequences extend beyond the individual test result. Delayed recognition of resistance may prolong ineffective treatment, while unnecessary use of broad-spectrum antibiotics can expose patients to avoidable risks and contribute to the selective pressure driving antimicrobial resistance (AMR). Developers are pursuing increasingly sophisticated technologies to address these problems, from rapid pathogen identification and resistance detection to predictive algorithms and prescribing guidance. However, the information these technologies generate must still influence decisions within busy, resource-constrained health care environments.
For developers, the clinical process connecting a result, prediction, or recommendation to a treatment decision should inform what they build and how they establish its value. That requires understanding the decision a technology is intended to change, designing the conditions under which clinicians can act on its outputs, and generating evidence that those actions produce meaningful benefits.
Start With the Decision That Needs to Change
A new antimicrobial technology typically begins with a defined scientific capability: identifying pathogens more quickly, detecting resistance mechanisms, predicting susceptibility, or analyzing clinical information to support treatment selection. Translating that capability into a useful product requires identifying the uncertainty it should resolve and the clinical behavior that should change as a result.
A physician selecting empiric antibiotics before susceptibility results become available faces a different problem from a pharmacist evaluating whether an existing regimen can be narrowed. An infectious disease specialist reviewing a complicated infection may need detailed microbiological and clinical context, while a clinician making an initial prescribing decision may need a concise recommendation that can be evaluated immediately. The information may originate from the same diagnostic or predictive platform, but its presentation, timing, and level of detail must reflect the decision being made.
Those differences also determine what information a technology must incorporate. A treatment recommendation that appears appropriate based on pathogen identification or predicted resistance may be unsuitable for a patient with relevant allergies, previous microbiological findings, or other treatment constraints. Developers therefore need to establish which clinical variables are necessary to support the proposed decision, whether those data will be available, and how missing or conflicting information should affect the recommendation.
Human-factors research can reveal these requirements before developers commit to a particular interface or implementation model. In a study published in the Proceedings of the International Symposium on Human Factors and Ergonomics in Health Care, researchers at The Ohio State University evaluated a prototype antibiotic stewardship decision-support system.1 Their work identified different requirements for clinicians making immediate patient-specific prescribing decisions and stewardship professionals conducting broader reviews. A system that provides comprehensive information for retrospective assessment may impose unnecessary work on a physician who needs to make a timely treatment decision.
Developers must also determine whether a recommendation should appear during antibiotic ordering, trigger a separate review, or prompt a change in responsibilities. The intended user needs both the information and the authority to act. These questions can expose weaknesses in the existing clinical process that a technology might address.
Researchers at the Perelman School of Medicine demonstrated this approach in a 2026 study published in Antimicrobial Stewardship & Healthcare Epidemiology.2 Qin and colleagues interviewed nurses and mapped urinary tract infection triage workflows before developing an electronic health record (EHR)–integrated clinical decision-support tool. The intervention incorporated structured symptom assessment into the triage process to guide decisions about testing and treatment. All 11 participating nurses met the study’s adoption threshold, although the tool was used in 60.8% of eligible encounters. Antibiotic prescribing for asymptomatic bacteriuria declined from 20% to 3%, while the reduction in overall unnecessary antibiotic prescribing was not statistically significant.
The small, single-center pre–post study cannot establish that the intervention caused the observed improvement or that similar results would occur elsewhere. Its importance for developers lies partly in the design process. Rather than simply presenting additional information, the researchers introduced a more structured assessment at a point where clinical decisions were already being made.
Workflow research may reveal that an existing process needs to change, not merely become faster or easier. A new assessment step, a different division of responsibilities, or an additional review may be justified if it addresses a source of inappropriate treatment. Defining the relationship between those changes and the anticipated clinical benefit provides a foundation for product requirements and subsequent evaluation.
Design the Path From Information to Action
For rapid bloodstream infection diagnostics, the opportunity to improve treatment depends on two connected processes: generating useful microbiological information and ensuring that the information leads to an appropriate clinical response. Each presents operational challenges that may limit the benefit of faster testing.
The first begins in the laboratory. Specimens must be collected, transported, loaded into instruments, processed, and analyzed. Delays at these stages can erode the time advantage offered by a rapid assay. In a prospective study published in 2023 the Journal of Global Antimicrobial Resistance, researchers at the All India Institute of Medical Sciences in Bhopal evaluated a diagnostic stewardship care-bundle incorporating staff training, checklists, and defined processing targets.3 The team found that median blood culture loading time decreased from 63.5 to 32 minutes, while the time to perform direct identification and susceptibility testing fell from 186 to 115 minutes. The study did not establish whether these improvements changed prescribing or patient outcomes, but it demonstrated how laboratory operations influence the time required to generate diagnostic information.
Once results are available, the challenge shifts to communication, interpretation, and treatment modification. A randomized controlled trial conducted by researchers at Korea University Anam Hospital and published in Clinical Infectious Diseases in 2026 examined this downstream process.4 The research team compared conventional blood culture identification and phenotypic antimicrobial susceptibility testing with standard care supplemented by a rapid multiplex polymerase chain reaction (PCR) panel. Both groups received routine antimicrobial stewardship support. Results were reported through the EHR, and treating clinicians received text notifications, with infectious diseases consultation recommended but left to clinical discretion.
Among 418 patients, the median time to the first effective antimicrobial modification was 23.2 hours with multiplex PCR, compared with 64.5 hours under standard care. Persistent bloodstream infections occurred in 5.7% and 11.5% of patients, respectively, a statistically significant difference. The investigators found no significant differences in 30-day mortality or length of stay.4 These results demonstrate improvements in treatment timing and one clinically meaningful infection outcome, while leaving open whether the intervention produces broader benefits across different patient populations and care settings.
The multicenter RAPIDS-GN randomized trial provides complementary evidence. In a study published in Clinical Infectious Diseases, researchers at the Vanderbilt University Medical Center evaluated rapid organism identification and phenotypic susceptibility testing for Gram-negative bloodstream infections, with antimicrobial stewardship review provided in both groups.5 The intervention shortened the median time to the first antibiotic modification from 14.9 to 8.6 hours. Among patients with resistant infections, the median time to antibiotic escalation decreased from 61.7 to 18.4 hours, although the trial did not identify significant differences in patient outcomes.
These results are consistent with broader evidence that the effects of rapid diagnostics depend partly on the clinical systems surrounding them. A systematic review and network meta-analysis conducted by researchers at Monash University and published in Clinical Infectious Diseases analyzed 88 studies encompassing 25,682 bloodstream infection encounters.6 Rapid diagnostics combined with antimicrobial stewardship were associated with lower mortality than conventional blood culture testing alone, whereas rapid testing without stewardship was not associated with a statistically significant survival benefit. Adding stewardship to rapid testing was also associated with a shorter time to optimal therapy.
The findings support evaluating diagnostics and stewardship as connected components of care, but they do not establish that stewardship independently caused the observed mortality differences or that every hospital requires the same implementation model. The underlying studies were heterogeneous, and many used nonrandomized designs. A separate meta-analysis of multiplex PCR blood culture identification studies did not find a significant difference in time-to-appropriate-therapy or length-of-stay effects when results were stratified by the presence of stewardship support.7 Because the analyses differed in study populations, interventions, and comparisons, their findings should not be interpreted as directly contradictory.
Laboratory coverage, automated reporting, clinician notification, specialist interpretation, and responsibility for treatment changes can all influence the interval between identifying resistance and modifying therapy. Understanding these dependencies influences how a diagnostic product is designed, integrated, and deployed.
Why Integration Does Not Guarantee Impact
Clinical decision-support systems introduce another challenge: even when a recommendation appears within an established prescribing workflow, clinicians may not use it, or its use may not produce the anticipated improvement.
The Intelligent Stewardship Prompts to Improve Real-time Empiric Antibiotic Selection (INSPIRE) trials provide evidence that targeted interventions can change prescribing behavior. In two cluster-randomized trials published in JAMA in 2024, Shruti Gohil of the University of California, Irvine, and colleagues from collaborating institutions evaluated stewardship interventions that incorporated patient-specific estimates of multidrug-resistant organism risk into antibiotic ordering.8,9 The interventions prompted clinicians to consider standard-spectrum antibiotics when patients had a low estimated risk of resistant infection, alongside education and feedback supporting more appropriate empiric prescribing.
Across 59 community hospitals, the interventions produced a 28.4% relative reduction in empiric extended-spectrum antibiotic days of therapy for pneumonia and a 17.4% relative reduction for urinary tract infections compared with routine stewardship. Neither trial identified significant differences in hospital length of stay or time to intensive care unit transfer, the reported safety outcomes. Because the interventions included multiple components, their effects cannot be attributed exclusively to the computerized prompts.
Other trials have shown that integration alone may have limited effects. The COMPASS cluster-randomized trial, published in The Lancet Infectious Diseases in 2022, evaluated an EHR-integrated antibiotic decision-support intervention across 24 wards in three Swiss hospitals.10 Despite its availability within prescribing systems, the intervention did not significantly reduce overall antibiotic use. Investigators identified limited uptake and delayed use as possible contributors, raising questions about whether clinicians encountered the recommendations at moments when they could meaningfully influence treatment.
A study led by a team at the University of Colorado School of Medicine and Children’s Hospital Colorado illustrates a different challenge.11 Published in Pediatrics in 2025, the stepped-wedge, cluster-randomized trial evaluated a machine-learning-based tool designed to identify children at risk of septic shock across four pediatric emergency departments. Clinicians generally regarded the system as acceptable and unobtrusive, and all four sites continued using it six months after the trial. Nevertheless, the intervention did not significantly improve its primary treatment-timing outcome or septic shock outcomes.
These findings point to different questions for developers. When clinicians rarely use an intervention, the investigation may begin with its timing, accessibility, relevance, or demands on the user. When a tool achieves sustained acceptance without improving its target outcomes, attention may need to shift toward the clinical premise: whether the recommendation addresses a consequential decision, whether the proposed action is effective, or whether existing care already achieves much of the anticipated benefit.
The differences among INSPIRE, COMPASS, and the Colorado study cannot be attributed to any single design characteristic. Their populations, interventions, clinical settings, and endpoints differ substantially. Nevertheless, the studies illustrate why deployment, engagement, changes in clinical behavior, and improvements in patient outcomes require separate evaluation.
Validate the Intervention, Not Just the Technology
The different outcomes of these trials have direct implications for clinical validation. Developers need evidence that a technology performs its technical function, but they also need to determine whether its users encounter the information at a meaningful point, respond appropriately, and produce the anticipated change in care.
A systematic review and meta-regression published in Implementation Science in 2022 illustrates why these measures cannot be overlooked.12 The investigators examined uptake of computerized clinical decision-support systems across 55 studies involving 373,608 patients and 3,607 health care providers. Their random-effects meta-analysis found an overall weighted uptake estimate of 34.2%, with a 95% confidence interval of 23.2%–47.1%. Among 443 studies that otherwise met eligibility criteria, only 55, or 12.4%, reported uptake. The researchers also identified associations between uptake and implementation activities addressing data quality, availability, and barriers to the targeted behavioral change.
Measuring uptake is necessary but does not fully establish whether an intervention was used as intended. A clinician opening a recommendation after completing an antibiotic order may count as a user without having had an opportunity to apply the information to the original decision. For technologies designed to influence time-sensitive treatment, evaluations may need to distinguish access at the relevant decision point from subsequent review.
These details can determine how developers interpret clinical trial results. If an intervention fails to change prescribing, usage data may reveal that clinicians rarely encountered its recommendations, encountered them too late, or reviewed them without changing treatment. Each possibility points toward a different development question. Improving predictive accuracy may have limited value if clinicians do not receive the information when it is needed, while redesigning an interface may not address an intervention whose recommendations offer little additional clinical benefit.
The relevant measures should follow the proposed mechanism of benefit. For rapid diagnostics, developers may need to evaluate analytical turnaround time, result availability, notification, treatment modification, and downstream clinical outcomes. For resistance-prediction tools, validation may need to connect predictive accuracy with changes in empiric antibiotic selection and the consequences of those changes for adequate treatment and unnecessary broad-spectrum exposure.
A 2026 systematic review and meta-analysis published in Open Forum Infectious Diseases illustrates why these endpoints must remain distinct.7 Researchers at Rochester General Hospital and collaborating institutions evaluated 20 studies involving 4,587 patients who underwent multiplex PCR blood culture identification testing. Across the studies contributing to the respective analyses, the technologies were associated with a mean reduction of 17.28 hours in time to appropriate therapy and 1.25 days in hospital length of stay. The researchers found no statistically significant mortality benefit or overall economic difference. Most included studies were nonrandomized, and heterogeneity was substantial for time to appropriate therapy, limiting the certainty and generalizability of the pooled estimates.
Earlier appropriate treatment remains a meaningful clinical objective even when mortality benefits have not been demonstrated. However, intermediate improvements should not be treated as proof of outcomes that have not been established. A technology intended to reduce unnecessary antibiotic exposure may require a different validation strategy from one intended to accelerate effective treatment of life-threatening infection.
Evidence generation should evolve with development. Human-factors studies can identify problems with comprehension and usability before routine deployment. Feasibility and implementation studies can establish whether clinical teams can execute the proposed process. Comparative effectiveness studies can then evaluate changes in treatment and patient outcomes. Defining the expected clinical response early helps developers select appropriate endpoints and collect the information needed to explain both positive and negative findings.
What Does It Take to Make the Benefit Reproducible?
Clinical studies establish what an intervention can achieve under particular conditions. Broader deployment requires understanding which of those conditions are necessary to reproduce the benefit in other institutions.
A rapid diagnostic platform evaluated in a hospital with continuous laboratory coverage and dedicated stewardship pharmacists may perform differently in a facility where specialist review is available only during certain hours. A decision-support system developed within a particular EHR may require substantial adaptation to function with different data structures, prescribing protocols, or clinical responsibilities. These differences influence the resources needed for implementation and may affect the consistency of clinical responses.
Research on commercial antimicrobial stewardship software demonstrates how much organizational work may be involved. In a mixed-methods study published in the International Journal of Medical Informatics in 2024, clinical researchers at the University of Lorraine and Nancy University Hospital in France examined the experiences of 11 antimicrobial stewardship professionals using a computerized decision-support system.13 Nine months after implementation, the researchers conducted interviews and assessed usability, identifying technical, organizational, and human factors affecting adoption. Collaboration with information technology teams was important for installation and configuration, while routine use required training, personnel, adaptation, and clinical leadership.
The system received a median System Usability Scale score of 77.5 out of 100, indicating favorable perceptions of ease of use. Nevertheless, the study identified continuing organizational requirements that favorable usability ratings alone could not address. Although the findings came from one institution, they illustrate why developers need to understand the work required to establish and maintain routine use.
These requirements also affect economic evaluations. In a 2017 study published in the Journal of Clinical Microbiology, researchers at the University of Michigan evaluated the introduction of matrix-assisted laser desorption ionization–time of flight mass spectrometry alongside real-time antimicrobial stewardship intervention for bloodstream infections.14 The team conducted a before-and-after cost analysis involving 480 patients, incorporating diagnostic equipment, supplies, personnel, and dedicated pharmacist time. Mean total hospital costs were $42,580 per bloodstream infection after implementation, compared with $45,019 before implementation, a difference of $2,439. Although the investigators estimated substantial annual savings, the difference in per-patient costs was not statistically significant, and the study could not isolate the economic contributions of the diagnostic and stewardship components.
A team from Brown University and Rhode Island Hospital explored the relationship between rapid diagnostics, stewardship, and economic outcomes in a decision-analytic study published in Clinical Microbiology Reviews in 2018.15 Their analysis suggested that rapid diagnostic strategies combined with antimicrobial stewardship could be cost-effective, but the projected benefits depended on assumptions about clinical outcomes, intervention costs, and implementation resources. These modeled findings provide a framework for economic evaluation rather than evidence that comparable savings will occur in every institution.
The implications extend into product architecture and deployment strategy. Interoperability requirements may influence software design, while dependence on specialist interpretation may affect the clinical settings for which a diagnostic platform is best suited. Systems that generate treatment recommendations may require ongoing updates as resistance patterns, clinical guidelines, and local formularies change. Developers and adopting institutions need to establish who will maintain these functions and how the intervention’s performance will be assessed over time.
Clinical results are more informative to prospective adopters when accompanied by a clear description of the staffing, infrastructure, training, and operational processes required to achieve them. Institutions can then assess whether their existing capabilities support the intervention or whether additional resources will be necessary.
Although these factors may influence commercial adoption, the available research does not establish a direct causal relationship between workflow compatibility and purchasing decisions. It supports a narrower conclusion: evaluating a technology’s clinical and economic value requires understanding the intervention as it will actually operate, including the resources and institutional commitments needed to deliver its benefits.
Developers cannot eliminate every implementation barrier. Staffing limitations, competing clinical priorities, and differences in local practice will continue to influence results. They can, however, identify important dependencies, evaluate alternative implementation arrangements, and provide guidance that makes the requirements for effective use more transparent.
Making Implementation Part of Innovation
Advances in antimicrobial diagnostics, resistance prediction, and clinical decision support are creating new opportunities to improve treatment decisions. Laboratory delays, limited engagement with recommendations, and uncertain clinical effects can each constrain their benefits, and each calls for a different development or implementation response.
For antimicrobial technology developers, understanding what happens after a result, prediction, or recommendation reaches the clinic should be part of defining the innovation itself. Those decisions shape what a product must deliver, how its clinical value is established, and whether its benefits can be reproduced beyond the setting in which it was developed.
